Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cetuximab + TAK-981 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 39 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
TAK-981 | TAK981|TAK 981 | TAK-981 is a small molecule inhibitor of SUMO, which may lead to activation of anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3252). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04065555 | Phase I | Avelumab + TAK-981 Cetuximab Cetuximab + TAK-981 TAK-981 Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Active, not recruiting | USA | 0 |